



## Bioshares Summit 2025

PIONEERING CELLULAR  
MEDICINES FOR  
WOMEN'S HEALTH

Targeting Ovarian Cancer and Endometriosis

• STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD. ACN: 602 297 807

AUGUST 2025



# Forward Looking Statements

---

This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such as 'could,' 'would,' 'may,' 'potentially,' 'suggest,' 'believes,' 'expects,' 'should,' 'intends,' 'plans,' 'forecasts,' and similar words or expressions.

Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including without limitation statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, pricing, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

The Company does not warrant any of the forward-looking statements in this presentation, and investors are advised to interpret such statements in the context of other available sources of information and with the assistance of expert advisors as appropriate.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Drug development is inherently risky, and only a small proportion of research and development programs lead to a marketed product. Factors which could change the Company's expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the

ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; changes in the competitive landscape pertaining to our drug development candidates; the timely availability of necessary capital to pursue our business objectives; changes in the public policy environment in one or more countries in which we operate or may seek to operate which disfavor our business; our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services; and other factors, including the COVID-19 pandemic and the conflicts in Ukraine and Middle East.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, and although they reflect our current views as at the date of this presentation, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to pursue any specific strategy or plan outlined herein, or to deliver any specific outcome that may be implied or inferred.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

# The Song of the Cell: An Exploration of Medicine and the New Human

“

Cellular physiology is thus the basis for human physiology, and **cellular pathology** is the basis for **human pathology**.

The capacity to build new humans out of our building blocks – i.e., cells – lies very much within the reach of medicine today; **cellular reengineering can ameliorate, or even reverse, cellular pathology.** ”

**Dr Siddhartha Mukherjee**

Oncologist

Researcher

Entrepreneur

Pulitzer Prize winner

# A Solid Foundation Built for Clinical Execution

## Significant Capital Investment & Validation



- >A\$79M in private capital, grants and R&D tax incentive.
- Funded creation of robust asset base.

## State-of-the-Art Infrastructure



- 1,800m<sup>2</sup> purpose-built R&D facility.
- Clinical manufacturing clean room facility established mid-2025.

## World-Class, Experienced Team



- Team of ~30 scientists and advisors.
- Led by pioneers in reproductive medicine and biotechnology.

Hospitals where we have clinical advisors and anticipated Phase I/IIa study sites:



Prince of Wales Hospital & Community Health Services

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.



# The Crippling Burden of Neglected Women's Health

## A Two-Part Crisis in Women's Health: A Lethal Cancer and a Debilitating Disease

1

### Ovarian Cancer

- ~325,000 new cases, ~200,000 deaths globally p.a.
- Limited treatment options.
- >75% cases diagnosed at stage III/IV.
- 5-year survival rate 41% (stage III), 20% (stage IV). <sup>[1]</sup>


2

### Endometriosis

- Affects 190 million women globally.
- Causes debilitating pain, organ damage, and infertility.
- No effective treatment or cure.
- Significant risk factor for ovarian cancer.

Strong link between ovarian cancer and endometriosis, with overlapping biology.

Cartherics is developing therapies that target specific antigens common to both diseases.



- **Our strategy:** Ovarian cancer as a gateway to treating the broader endometriosis crisis.


[1] [ocrahope.org/get-the-facts/staging/#stage-4](https://ocrahope.org/get-the-facts/staging/#stage-4)

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

# Our Solution:

## A Scalable, "Off-the-Shelf" Cellular Medicine Platform

Pioneering a New Standard in Women's Health:  
A Platform Built on Safety, Potency, and Accessibility.



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

# Our Pipeline: A Phased Approach to Clinical Expansion

A Deliberate Strategy: Validate the Platform, Then Unleash its Full Potential.

1

## Program 1: CTH-401 iNK Cells, Lead Program

- **Edits:** TAG-72 CAR, DGK KO iNK cells.
- **Indications:** Relapsed/refractory ovarian cancer; expansion to other TAG-72+ solid tumors and endometriosis.

2

## Program 2: CTH-501 iNK Cells, Next-Generation Target

- **Edits:** TF / TAG-72 CAR.
- **Indication:** Endometriosis.

3

## Program 3: CTH-502, TME- Resistant iNK Cells

- **Edits:** TF / TAG-72 CAR plus multiple gene edits for TME resistance.
- **Indications:** Ovarian cancer, TNBC, other TAG-72+ and/or TF+ solid tumors.

4

## Program 4: Platform Expansion: Extracellular Vesicles

- **Concept:** Non-cellular therapies derived from iNK cells. Potential for non-systemic delivery (e.g., intra-nasal delivery).


STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

# Our Gateway Strategy: From an Orphan Disease to a Global Market

## A Smart Gateway to a Massive Market

### Our Strategy:

1. **Start with Ovarian Cancer:** Qualifies for Orphan Drug Status.
2. **Establish a Safety Bridge:** FIH data in cancer will establish dose and safety to treat “healthy” patients.
3. **Bridge to the Broader Market:** Safety data provide basis for expansion into endometriosis market (**190 million women worldwide**), where underlying disease drivers may be shared.



STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.



# Use of Funds: Accelerating Our Pipeline to Key Clinical Milestones

**The Ask:** Seeking **A\$15M–A\$20M** to fully fund operations through to key clinical and preclinical inflection points across our pipeline to the end of FY2027.

## Allocation of Capital

- **Achieve Clinical Proof-of-Concept for CTH-401:** Clinical manufacturing; IND submission; initiation of FIH trial in ovarian cancer; preclinical PoC for endometriosis.
- **Propel Next-Generation CTH-501 & CTH-502 to the Clinic:** Full preclinical data packages; initiate IND-enabling studies.
- **Advance Core Platform & Operations:** Enhance iPSC-NK platform; expand IP portfolio; fund general operations.

STRICTLY CONFIDENTIAL AND PROPRIETARY TO CARTHERICS PTY LTD.

# Contact Details

# CARTherics

## Prof Alan Trounson

Chief Executive Officer  
[alan.trounson@cartherics.com](mailto:alan.trounson@cartherics.com)

## Dr Ian Nisbet

Chief Operating Officer  
[ian.nisbet@cartherics.com](mailto:ian.nisbet@cartherics.com)

CARTHERICS PTY LTD  
12 Ferntree Place  
Notting Hill VIC 3168  
AUSTRALIA  
(ACN 602 297 807)

 [cartherics.com](http://cartherics.com)

 [linkedin.com/company/cartherics-pty-ltd/](https://linkedin.com/company/cartherics-pty-ltd/)

 [youtube.com/watch?v=6tOfmMDals&t=10s](https://youtube.com/watch?v=6tOfmMDals&t=10s)

TERRAINCAPITAL

## Corporate Advisor

**Dominic Marinelli**

Terrain Capital Limited  
8 Chapel Street,  
Richmond, VIC 3121  
M: +61 405 269 536  
[dmarinelli@terraincapital.com](mailto:dmarinelli@terraincapital.com)

